Printer Friendly

New asthma treatment guidelines.

The 2004 asthma treatment guidelines for pregnant women, issued by the National Asthma Education and Prevention Program last month, is an extremely valuable document that meets a great need for guidance in this area. The guidelines, which also include a table on the stepwise approach to managing asthma in pregnancy, are the first to be issued on treating asthma in pregnant women in more than 10 years.

A better understanding of the inflammatory nature of the disease has promoted a major shift in therapy. Anti-inflammatory medications, most notably corticosteroids, and mast cell stabilizers (leukotriene inhibitors) are the first-line drugs of current treatment. Until 20 years ago, the hallmark treatment was theophylline. Although this agent is rarely used today to treat asthma, the guidelines say at recommended doses, it is safe during pregnancy.

The authors of the document, a multidisciplinary expert panel, performed a systematic review of the available evidence on asthma treatment in pregnancy. Some of the key findings are:

* Inhaled corticosteroids can reduce the risk of asthma exacerbations and improve lung function. There is no evidence that inhaled corticosteroids are linked to adverse outcomes. When taken through the inhaled route, systemic exposure is much less than with oral corticosteroids. Budesonide has the most data backing its safety in pregnancy, making it the "preferred inhaled corticosteroid," according to the guidelines. But the document points out that there are no data indicating the other agents are unsafe in pregnancy.

* Oral corticosteroids may be necessary for treating women with severe asthma. While there are conflicting data on their safety in pregnancy, they may be warranted in women with severe disease, according to the guidelines. In the general population, there is an association between use of oral corticosteroids in the first trimester and an increased risk for cleft lip and or palate, compared with nonuse (0.3% vs. 0.1%), but not many asthmatic pregnant women have been included in these studies.

This risk for oral cleft has been shown in animals and in humans. Our Motherisk Program systematically reviewed studies and found a two- to threefold increase in oral cleft (with first-trimester exposure), which probably is not the case for inhaled steroids because the systemic dose is much smaller. Clearly, patients who are prescribed oral corticosteroids in the first trimester should be informed of this risk.

During the second and third trimester, oral steroids cannot cause malformations. However, there are studies, which do not include patients with asthma, indicating that systemic exposure to corticosteroids may be associated with some CNS damage in babies. Most of these data were from studies of premature infants whose mothers received corticosteroids to enhance lung maturation.

There is evidence that repeating the dose of corticosteroids more than once may increase the risk of adverse brain outcome in premature babies. If a woman needs high-dose corticosteroids late in pregnancy, such a possibility should be discussed with her before prescribing these agents.

* The short-acting [[beta].sub.2]-agonist albuterol is the preferred drug in this class for treating acute symptoms, and the available data on the safety of [[beta].sub.2]-agonists are reassuring, the guidelines say. Albuterol has been studied in many millions of patients worldwide and in thousands of pregnant women, and there is no indication whatsoever that it has any teratogenic effects. Since it is inhaled, systemic exposure is not great.

* For women with persistent asthma who are not well controlled on low dose inhaled corticosteroids, increasing the dose or adding a long-acting [beta]-agonist is recommended, but there are not enough data indicating which approach is preferable, according to the guidelines. It is fair to say that [beta]-agonists have not been shown to be teratogenic.

* Cromolyn, used as a preventive treatment, appears to be safe, based on available evidence, the guidelines state.

* Leukotriene modifiers, as the document notes, have "minimal" data available on their use in pregnancy, although there are some reassuring animal data. We at Motherisk are prospectively collecting information on cases of pregnant women exposed to these drugs, and based on our experience, they do not appear to be major teratogens.

(A copy of the guidelines issued by the National Asthma Education and Prevention Program, which is administered by the National Heart, Lung and Blood Institute, can be found at


DR. KOREN is professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto, and holds the Ivey Chair in Molecular Toxicology at the University of Western Ontario, London. He has the Research Leadership in Better Pharmacotherapy During Pregnancy and Lactation at the Hospital for Sick Children, Toronto, where he also serves as director of the Motherisk Program.
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Koren, Gideon
Publication:OB GYN News
Date:Feb 15, 2005
Previous Article:Melanoma and pregnancy: 'prompt biopsy is key'.
Next Article:First-trimester stress may prompt early delivery.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters